| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/4/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| +6.63% | +5.13% | +68.86% | +145.20% | 1,224B | |
| +1.53% | +2.84% | +47.48% | +89.01% | 662B | |
| +1.68% | +1.96% | +29.16% | +109.31% | 514B | |
| +0.75% | +3.22% | +54.18% | +67.22% | 388B | |
| +3.83% | -0.62% | +69.01% | +42.32% | 361B | |
| +0.83% | +4.52% | +35.30% | +58.08% | 302B | |
| +3.17% | +4.83% | +7.16% | +31.57% | 271B | |
| +1.97% | +3.01% | +57.91% | +76.14% | 249B | |
| +4.03% | +5.36% | +39.76% | +116.14% | 205B | |
| Average | +2.78% | +2.59% | +45.42% | +81.67% | 464.09B | |
| Weighted average by Cap. | +2.22% | +3.04% | +50.72% | +96.51% |
Employees
2,191
Sector
Pharmaceuticals
